Signs and Artifacts in Amyloid PET

Tamara F. Lundeen, John P. Seibyl, Matthew F. Covington, Naghmehossadat Eshghi, Phillip H Kuo

Research output: Contribution to journalArticle

Abstract

Establishing a diagnosis of Alzheimer dementia can be challenging, particularly early in the course of the disease. However, with disease-modifying therapies on the horizon, it is becoming increasingly important to achieve the correct diagnosis as soon as possible. In challenging presentations of dementia, such as patients with clinically atypical features or early-age onset of mild cognitive impairment, amyloid PET is a valuable tool in determining the diagnosis of Alzheimer dementia. Furthermore, preliminary data show that amyloid PET findings alter clinical management in patients who meet the appropriate use criteria. There are currently three U.S. Food and Drug Administration (FDA)-approved fluorine 18 (18F)-labeled radiopharmaceuticals that allow in vivo detection of cerebral amyloid deposition, which is a hallmark pathologic feature of Alzheimer dementia. Knowledge of the common imaging features among these three 18F-labeled radiopharmaceuticals in the normal and abnormal brain will enable the radiologist to more accurately interpret amyloid PET studies. As in other subspecialties of radiology, imaging signs in amyloid PET are helpful to distinguish if a region is normal or abnormal. This article reviews appropriate use criteria for amyloid PET, introduces the properties of the radiopharmaceuticals, explains the algorithmic approach to interpretation with examples of normal and abnormal amyloid PET scans with MRI correlation, and provides an atlas of regional amyloid PET signs and common artifacts.

Original languageEnglish (US)
Pages (from-to)2123-2133
Number of pages11
JournalRadiographics : a review publication of the Radiological Society of North America, Inc
Volume38
Issue number7
DOIs
StatePublished - Nov 1 2018

Fingerprint

Amyloid
Artifacts
Radiopharmaceuticals
Alzheimer Disease
Fluorine
Atlases
United States Food and Drug Administration
Age of Onset
Radiology
Positron-Emission Tomography
Dementia
Brain

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Signs and Artifacts in Amyloid PET. / Lundeen, Tamara F.; Seibyl, John P.; Covington, Matthew F.; Eshghi, Naghmehossadat; Kuo, Phillip H.

In: Radiographics : a review publication of the Radiological Society of North America, Inc, Vol. 38, No. 7, 01.11.2018, p. 2123-2133.

Research output: Contribution to journalArticle

Lundeen, Tamara F. ; Seibyl, John P. ; Covington, Matthew F. ; Eshghi, Naghmehossadat ; Kuo, Phillip H. / Signs and Artifacts in Amyloid PET. In: Radiographics : a review publication of the Radiological Society of North America, Inc. 2018 ; Vol. 38, No. 7. pp. 2123-2133.
@article{bb1a673fa74540f58d06247c0873a23b,
title = "Signs and Artifacts in Amyloid PET",
abstract = "Establishing a diagnosis of Alzheimer dementia can be challenging, particularly early in the course of the disease. However, with disease-modifying therapies on the horizon, it is becoming increasingly important to achieve the correct diagnosis as soon as possible. In challenging presentations of dementia, such as patients with clinically atypical features or early-age onset of mild cognitive impairment, amyloid PET is a valuable tool in determining the diagnosis of Alzheimer dementia. Furthermore, preliminary data show that amyloid PET findings alter clinical management in patients who meet the appropriate use criteria. There are currently three U.S. Food and Drug Administration (FDA)-approved fluorine 18 (18F)-labeled radiopharmaceuticals that allow in vivo detection of cerebral amyloid deposition, which is a hallmark pathologic feature of Alzheimer dementia. Knowledge of the common imaging features among these three 18F-labeled radiopharmaceuticals in the normal and abnormal brain will enable the radiologist to more accurately interpret amyloid PET studies. As in other subspecialties of radiology, imaging signs in amyloid PET are helpful to distinguish if a region is normal or abnormal. This article reviews appropriate use criteria for amyloid PET, introduces the properties of the radiopharmaceuticals, explains the algorithmic approach to interpretation with examples of normal and abnormal amyloid PET scans with MRI correlation, and provides an atlas of regional amyloid PET signs and common artifacts.",
author = "Lundeen, {Tamara F.} and Seibyl, {John P.} and Covington, {Matthew F.} and Naghmehossadat Eshghi and Kuo, {Phillip H}",
year = "2018",
month = "11",
day = "1",
doi = "10.1148/rg.2018180160",
language = "English (US)",
volume = "38",
pages = "2123--2133",
journal = "Radiographics",
issn = "0271-5333",
publisher = "Radiological Society of North America Inc.",
number = "7",

}

TY - JOUR

T1 - Signs and Artifacts in Amyloid PET

AU - Lundeen, Tamara F.

AU - Seibyl, John P.

AU - Covington, Matthew F.

AU - Eshghi, Naghmehossadat

AU - Kuo, Phillip H

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Establishing a diagnosis of Alzheimer dementia can be challenging, particularly early in the course of the disease. However, with disease-modifying therapies on the horizon, it is becoming increasingly important to achieve the correct diagnosis as soon as possible. In challenging presentations of dementia, such as patients with clinically atypical features or early-age onset of mild cognitive impairment, amyloid PET is a valuable tool in determining the diagnosis of Alzheimer dementia. Furthermore, preliminary data show that amyloid PET findings alter clinical management in patients who meet the appropriate use criteria. There are currently three U.S. Food and Drug Administration (FDA)-approved fluorine 18 (18F)-labeled radiopharmaceuticals that allow in vivo detection of cerebral amyloid deposition, which is a hallmark pathologic feature of Alzheimer dementia. Knowledge of the common imaging features among these three 18F-labeled radiopharmaceuticals in the normal and abnormal brain will enable the radiologist to more accurately interpret amyloid PET studies. As in other subspecialties of radiology, imaging signs in amyloid PET are helpful to distinguish if a region is normal or abnormal. This article reviews appropriate use criteria for amyloid PET, introduces the properties of the radiopharmaceuticals, explains the algorithmic approach to interpretation with examples of normal and abnormal amyloid PET scans with MRI correlation, and provides an atlas of regional amyloid PET signs and common artifacts.

AB - Establishing a diagnosis of Alzheimer dementia can be challenging, particularly early in the course of the disease. However, with disease-modifying therapies on the horizon, it is becoming increasingly important to achieve the correct diagnosis as soon as possible. In challenging presentations of dementia, such as patients with clinically atypical features or early-age onset of mild cognitive impairment, amyloid PET is a valuable tool in determining the diagnosis of Alzheimer dementia. Furthermore, preliminary data show that amyloid PET findings alter clinical management in patients who meet the appropriate use criteria. There are currently three U.S. Food and Drug Administration (FDA)-approved fluorine 18 (18F)-labeled radiopharmaceuticals that allow in vivo detection of cerebral amyloid deposition, which is a hallmark pathologic feature of Alzheimer dementia. Knowledge of the common imaging features among these three 18F-labeled radiopharmaceuticals in the normal and abnormal brain will enable the radiologist to more accurately interpret amyloid PET studies. As in other subspecialties of radiology, imaging signs in amyloid PET are helpful to distinguish if a region is normal or abnormal. This article reviews appropriate use criteria for amyloid PET, introduces the properties of the radiopharmaceuticals, explains the algorithmic approach to interpretation with examples of normal and abnormal amyloid PET scans with MRI correlation, and provides an atlas of regional amyloid PET signs and common artifacts.

UR - http://www.scopus.com/inward/record.url?scp=85056505347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056505347&partnerID=8YFLogxK

U2 - 10.1148/rg.2018180160

DO - 10.1148/rg.2018180160

M3 - Article

VL - 38

SP - 2123

EP - 2133

JO - Radiographics

JF - Radiographics

SN - 0271-5333

IS - 7

ER -